Document Detail

Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
MedLine Citation:
PMID:  14586719     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Insufficiency of renal function and high blood pressure influence each other and eventually result in life-threatening endstage renal disease. It has been proposed that proteinuria per se is a determinant of the progression of chronic kidney disease (CKD). The therapeutic strategy for patients with proteinuric CKD and hypertension should therefore be targeted with a view not merely toward blood pressure reduction but also toward renoprotection. METHODS: We examined the effect of the angiotensin (AT)1 receptor antagonist losartan and the calcium channel blocker amlodipine, throughout a period of 12 months, on reduction of blood pressure and renoprotection. This was done by assessing amounts of urinary protein excretion, serum creatinine (SCr), and creatinine clearance (CCr) in patients with hypertension (systolic blood pressure [SBP] > or = 140 mmHg or diastolic blood pressure [DBP] > or = 90 mmHg) and CKD (male, body weight [BW] > or = 60 kg: 1.5 < or = SCr < 3.0 mg/dl; female or male BW < 60 kg: 1.3 < or = SCr < 3.0 mg/dl), manifesting proteinuria of 0.5 g or more/day. Losartan was administered once daily at doses of 25 to 100 mg/day, and amlodipine was given once daily at 2.5 to 5 mg/day. No antihypertensive combination therapy was allowed during the first 3-month period. RESULTS: A 3-month interim analysis revealed that, despite there being no difference in blood pressure between the two groups, there was a significant reduction in 24-h urinary protein excretion in the losartan group ( n = 43), but there was no change in the amlodipine group ( n = 43). Analysis of stratified subgroups with proteinuria of 2 g or more/day and less than 2 g/day showed that losartan lowered proteinuria by approximately 24% in both subgroups, while amlodipine lowered proteinuria by 10%, but only in the subgroup of less than 2 g/day (NS). SCr and CCr did not change throughout the period of 3 months in either group. No severe or fatal adverse event was experienced in either group during the study period. CONCLUSIONS: Losartan appeared to be efficacious for renoprotection in patients with proteinuric CKD and hypertension, with the mechanism being independent of its antihypertensive action.
Yasuhiko Iino; Matsuhiko Hayashi; Tetsuya Kawamura; Tatsuo Shiigai; Yasuhiko Tomino; Kenichi Yamada; Takeyuki Kitajima; Terukuni Ideura; Akio Koyama; Tetsuzo Sugisaki; Hiromichi Suzuki; Satoshi Umemura; Yoshindo Kawaguchi; Shunya Uchida; Michio Kuwahara; Tsutomu Yamazaki;
Related Documents :
16117979 - Clinic blood pressure responses to two amlodipine salt formulations, adipate and besyla...
780059 - Indoramin in the treatment of hypertension: a placebo controlled trial.
788759 - Hydrallazine or phentolamine as adjuncts to beta-adrenoceptor blockade/thiazide therapy...
1395119 - Angiotensin-converting enzyme inhibition as first-line treatment for hypertension.
21720269 - High blood pressure and obesity: disparities among four french overseas territories.
7048879 - Effects of pindolol and methyldopa on blood pressure and plasma norepinephrine.
12345129 - Does migration arbitrage regional labor market differentials?
16162779 - Comparison of initial distribution volume of glucose and intrathoracic blood volume dur...
9523769 - The influence of restraint on blood pressure in the rat.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Clinical and experimental nephrology     Volume:  7     ISSN:  1342-1751     ISO Abbreviation:  Clin. Exp. Nephrol.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-10-30     Completed Date:  2003-12-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9709923     Medline TA:  Clin Exp Nephrol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  221-30     Citation Subset:  IM    
Second Department of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amlodipine / therapeutic use*
Antihypertensive Agents / therapeutic use*
Blood Pressure / drug effects
Calcium Channel Blockers / therapeutic use*
Hypertension, Renal / drug therapy*
Kidney Failure, Chronic / drug therapy*
Losartan / therapeutic use*
Middle Aged
Proteinuria / drug therapy
Receptors, Angiotensin / antagonists & inhibitors
Reg. No./Substance:
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Receptors, Angiotensin; 114798-26-4/Losartan; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-conv...
Next Document:  Determinants of prescribed dialysis dose and survival in a cohort of chronic hemodialysis patients.